Scilex announces production increase , availability of ELYXYB

Scilex announced the increase of ELYXYB manufacturing to meet its rising demand for ELYXYB and increased stocking needs in its distribution center. Scilex has met another significant corporate objective and produced our first commercial batch with Scilex labeled ELYXYB which will enable the Company to meet the growing demands of future customers seeking a rapid onset pain management regimen for the acute treatment of migraine. The company believes ELYXYB is the first and only ready to use oral solution designed to deliver fast and long-lasting migraine relief with the proven safety of COX-2 selectivity that is FDA-approved for the acute treatment of migraine, with or without aura, in adults. ELYXYB was studied in two randomized, double-blind trials of 1,253 patients with episodic migraine. ELYXYB treated patients demonstrated pain relief in as little as 15 minutes and significant pain relief compared to placebo within 45 minutes in nearly 50% of patients. Approximately 36% of patients were pain free at two hours. “We are very excited about the potential of ELYXYB(R) since the launch of the product in April 2023. This is a highly complementary commercial asset that allows us to provide physicians with another tool in their pain management armamentarium to treat migraines earlier in the patient journey as we continue to work towards redefining the role of opioids as a last resort rescue medication,” said Jaisim Shah, Chief Executive Officer and President of Scilex.